Your browser doesn't support javascript.
loading
Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma.
Tanaka, Yu; Nakai, Tokiko; Suzuki, Ayako; Kagawa, Yosuke; Noritake, Osamu; Taki, Tetsuro; Hashimoto, Hiroko; Sakai, Tetsuya; Shibata, Yuji; Izumi, Hiroki; Nosaki, Kaname; Udagawa, Hibiki; Zenke, Yoshitaka; Matsumoto, Shingo; Yoh, Kiyotaka; Miyazaki, Saori; Sakamoto, Naoya; Sakashita, Shingo; Kojima, Motohiro; Watanbe, Reiko; Tsuboi, Masahiro; Goto, Koichi; Ishii, Genichiro.
Afiliação
  • Tanaka Y; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Nakai T; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Suzuki A; Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Kagawa Y; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Noritake O; Department of Computational Biology and Medical Sciences, The University of Tokyo, Kashiwa, Chiba, Japan.
  • Taki T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Hashimoto H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Sakai T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Shibata Y; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Izumi H; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Nosaki K; Division of Innovative Pathology and Laboratory Medicine, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Udagawa H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Zenke Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Matsumoto S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Miyazaki S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Sakamoto N; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Sakashita S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Kojima M; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Watanbe R; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Tsuboi M; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Goto K; Division of Pathology, Exploratory Oncology Research, and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Ishii G; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Cancer Immunol Immunother ; 72(7): 2205-2215, 2023 Jul.
Article em En | MEDLINE | ID: mdl-36862151
ABSTRACT

INTRODUCTION:

This study aimed to clarify the correlation between the number of AMs and prognosis and to examine the gene expression of AMs in lung squamous cell carcinoma (SqCC).

METHODS:

We reviewed 124 stage I lung SqCC cases in our hospital and 139 stage I lung SqCC cases in The Cancer Genome Atlas (TCGA) cohort in this study. We counted the number of AMs in the peritumoral lung field (P-AMs) and in the lung field distant from the tumor (D-AMs). Moreover, we performed a novel ex vivo bronchoalveolar lavage fluid (BALF) analysis to select AMs from surgically resected lung SqCC cases and examined the expression of IL10, CCL2, IL6, TGFß, and TNFα (n = 3).

RESULTS:

Patients with high P-AMs had significantly shorter overall survival (OS) (p < 0.01); however, patients with high D-AMs did not have significantly shorter OS. Moreover, in TCGA cohort, patients with high P-AMs had a significantly shorter OS (p < 0.01). In multivariate analysis, a higher number of P-AMs were an independent poor prognostic factor (p = 0.02). Ex vivo BALF analysis revealed that AMs collected from the tumor vicinity showed higher expression of IL10 and CCL2 than AMs from distant lung fields in all 3 cases (IL-10 2.2-, 3.0-, and 10.0-fold; CCL-2 3.0-, 3.1-, and 3.2-fold). Moreover, the addition of recombinant CCL2 significantly increased the proliferation of RERF-LC-AI, a lung SqCC cell line.

CONCLUSION:

The current results indicated the prognostic impact of the number of peritumoral AMs and suggested the importance of the peritumoral tumor microenvironment in lung SqCC progression.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article